Context Therapeutics Inc. (CNTX)
CNTX Stock Price Chart
Explore Context Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze CNTX price movements and trends.
CNTX Company Profile
Discover essential business fundamentals and corporate details for Context Therapeutics Inc. (CNTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Oct 2021
Employees
12.00
CEO
Martin A. Lehr
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Financial Timeline
Browse a chronological timeline of Context Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.09.
Earnings released on 6 Aug 2025
EPS came in at -$0.09 falling short of the estimated -$0.06 by -50.00%.
Earnings released on 7 May 2025
EPS came in at -$0.05 matching the estimated -$0.05.
Earnings released on 20 Mar 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 6 Nov 2024
EPS came in at -$0.22 falling short of the estimated -$0.11 by -100.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%.
Earnings released on 8 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.38 by +39.47%.
Earnings released on 21 Mar 2024
EPS came in at -$0.42 falling short of the estimated -$0.35 by -20.00%, while revenue for the quarter reached $18.95K .
Earnings released on 9 Nov 2023
EPS came in at -$0.37 falling short of the estimated -$0.30 by -23.33%.
Earnings released on 9 Aug 2023
EPS came in at -$0.31 falling short of the estimated -$0.20 by -55.00%.
Earnings released on 10 May 2023
EPS came in at -$0.40 falling short of the estimated -$0.19 by -110.53%.
Earnings released on 22 Mar 2023
EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%.
Earnings released on 9 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%.
Earnings released on 11 Aug 2022
EPS came in at -$0.25 matching the estimated -$0.25.
Earnings released on 11 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.24 by +8.33%.
Earnings released on 24 Mar 2022
EPS came in at -$0.30 falling short of the estimated -$0.27 by -12.16%.
Earnings released on 2 Dec 2021
EPS came in at -$4.00 .
Earnings released on 30 Jun 2021
EPS came in at -$0.73 .
Earnings released on 31 Mar 2021
EPS came in at -$0.09 .
Earnings released on 31 Dec 2020
EPS came in at -$0.08 .
Earnings released on 30 Sept 2020
EPS came in at -$0.09 .
CNTX Stock Performance
Access detailed CNTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.